How did OFIX's Q1 2025 EPS forecast compare to past trends?

Orthofix Medical Inc.'s (OFIX) Q1 2025 EPS forecast is not currently available. However, we can analyze the company's historical EPS trends to provide insights into its potential future performance. 1. **Historical EPS Performance**: - OFIX's EPS has been volatile, with significant fluctuations from year to year. - The company's EPS has improved from a loss of $1.71 in Q1 2023 to a loss of $0.71 in Q3 2023, indicating a reduction in losses over time. - In Q1 2024, OFIX's EPS was -$0.95, which is an improvement from the -$1.66 reported in Q1 2023. 2. **Comparison to Financial Estimates**: - Analysts have forecasted an EPS of $0.06 for Q1 2025, which suggests a potential improvement from the previous quarter's EPS of -$0.95. - It's important to note that the Q1 2025 EPS forecast is not currently available, so comparisons to past trends are limited without a specific figure. 3. **Revenue Trends and Strategic Shifts**: - Orthofix has reported record sales and strategic shifts, with an 8% increase in Q4 net sales and a 7% increase in full-year net sales. - The company's adjusted EBITDA has grown by 22% in Q4 compared to the previous year, indicating improved profitability. 4. **Market Analysts' Perspectives**: - Citizens JMP analysts maintain a "Market Perform" rating for OFIX after the Q4 earnings release, which may suggest a cautious outlook for the upcoming quarter. - The average analyst price target for OFIX is $24.30, with an upside potential of 33.88% from the current price, which could imply confidence in the company's future performance. In conclusion, while OFIX's Q1 2025 EPS forecast is not currently available, the company's historical EPS trends show improvements over time. The strategic shifts and increased net sales guidance suggest a positive outlook, although the "Market Perform" rating and the need to discontinue less profitable product lines may pose some challenges.